KLRA Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

24.190

Open

23.000

VWAP

23.30

Vol

555.94K

Mkt Cap

2.97B

Low

22.765

Amount

12.95M

EV/EBITDA(TTM)

Total Shares

129.57M

3.44B

EV/OCF(TTM)

P/S(TTM)

Kailera Therapeutics Inc is a United States-based company. The Company is a clinical-stage biopharmaceutical company developing a broad and advanced therapeutic pipeline that is poised to deliver differentiated treatment options for obesity and related conditions. Its pipeline consists of clinical- and preclinical-stage programs with injectable peptides, oral peptides, and an oral small molecule.

Events Timeline

(ET)

2026-05-11

11:30:00

Mobia Medical, Odyssey Therapeutics and Others Go Public This Week

2026-04-22 (ET)

2026-04-22

08:20:00

PMV Pharmaceuticals Board Transition, Laurie Stelzer Appointed New Chair

2026-04-20 (ET)

2026-04-20

11:30:00

AEVEX Opens Above $20 in IPO Debut

2026-04-17 (ET)

2026-04-17

13:30:00

Kailera Therapeutics Prices 39.06M Shares at $16.00

News

8.5

05-26seekingalpha

Kailera Therapeutics Reports Q1 Net Loss of $78.9 Million

8.5

05-16Fool

Kailera Therapeutics Makes Successful IPO Amid Biotech Surge

8.5

05-13Newsfilter

Hengrui Pharma and Kailera Showcase New Drug at ADA

6.0

05-12CNBC

Latest Wall Street Ratings Overview

8.5

05-08Newsfilter

Odyssey Therapeutics Raises $279 Million in Upsized IPO

8.5

05-01renaissancecapital

April IPO Market Rebounds with $7.3 Billion Raised

0 Analyst Rating

Wall Street analysts forecast KLRA stock price to rise

0 Buy

0 Hold

0 Sell

Current: 0.000

Low

Averages

High

Current: 0.000

Low

Averages

High

Evercore ISI

Umer Raffat

initiated

AI Analysis

2026-05-12

Reason

Evercore ISI

Umer Raffat

Price Target

AI Analysis

2026-05-12

initiated

Reason

Evercore ISI analyst Umer Raffat initiated coverage of Kailera Therapeutics with an Outperform rating and no price target. Kailera is \"making waves in the GIP-GLP space with impressive early-stage data,\" says the analyst, who notes that a head-to-head trial against semaglutide is underway in China, with data expected in early 2027. Initial expectations suggest Kailera could outperform semaglutide by at least 6 percentage points in weight loss, though \"the full potential of oral formulations may take time to unfold,\" the analyst added.

Leerink

Outperform

initiated

$36

2026-05-12

Reason

Leerink

Price Target

$36

2026-05-12

initiated

Outperform

Reason

Leerink initiated coverage of Kailera Therapeutics (KLRA) with an Outperform rating and $36 price target. The firm believes the company's obesity candidate offer key advantages relative to competing assets, including potential injectable ribupatide efficacy greater than Eli Lilly's (LLY) tirzepatide and oral ribupatide advantages over Novo Nordisk's (NVO) oral Wegovy and Lilly's Foundayo. The company is also leveraging high-quality R&D from China's number one biopharma company, Henguri, Leerink says, adding that Kailera has exceptional leadership with proven track records.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KLRA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Kailera Therapeutics Inc (KLRA.O) is 0.00, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess Kailera Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

Current PE

0.00

Overvalued PE

Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

Current PS

0.00

Overvalued PS

Undervalued PS

Financials

AI Analysis

Annual

Quarterly

Whales Holding KLRA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Kailera Therapeutics Inc (KLRA) stock price today?

The current price of KLRA is 22.94 USD — it has increased 0

What is Kailera Therapeutics Inc (KLRA)'s business?

What is the price predicton of KLRA Stock?

Wall Street analysts forecast KLRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KLRA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Kailera Therapeutics Inc (KLRA)'s revenue for the last quarter?

Kailera Therapeutics Inc revenue for the last quarter amounts to -84.66M USD, decreased

What is Kailera Therapeutics Inc (KLRA)'s earnings per share (EPS) for the last quarter?

Kailera Therapeutics Inc. EPS for the last quarter amounts to USD, decreased

How many employees does Kailera Therapeutics Inc (KLRA). have?

Kailera Therapeutics Inc (KLRA) has 145 emplpoyees as of May 30 2026.

What is Kailera Therapeutics Inc (KLRA) market cap?

Today KLRA has the market capitalization of 2.97B USD.

KLRA Overview

KLRA Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Whales Holding KLRA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Kailera Therapeutics Inc (KLRA) stock price today?

What is Kailera Therapeutics Inc (KLRA)'s business?

What is the price predicton of KLRA Stock?

What is Kailera Therapeutics Inc (KLRA)'s revenue for the last quarter?

What is Kailera Therapeutics Inc (KLRA)'s earnings per share (EPS) for the last quarter?

How many employees does Kailera Therapeutics Inc (KLRA). have?

What is Kailera Therapeutics Inc (KLRA) market cap?